AstraZeneca shares are trading higher after Enhertu was approved in China for HER2-low metastatic breast cancer.
Portfolio Pulse from Benzinga Newsdesk
AstraZeneca's shares are trading higher following the approval of Enhertu in China for the treatment of HER2-low metastatic breast cancer.
July 12, 2023 | 2:50 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AstraZeneca's stock is trading higher due to the approval of Enhertu in China for HER2-low metastatic breast cancer treatment.
The approval of Enhertu in China, a large market, for the treatment of HER2-low metastatic breast cancer is a significant positive development for AstraZeneca. This is likely to boost the company's revenues and profitability, leading to a positive impact on its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100